01 / DESIGN
What was studied?
An open-label randomized trial compared tesamorelin with standard care for six months in people with HIV and abdominal obesity.
02 / FINDINGS
What did the researchers report?
Waist circumference decreased more in the tesamorelin group, but neurocognitive change did not differ significantly between groups.
03 / LIMITS
How should it be interpreted?
A within-group trend is not a positive randomized comparison. The small study lacked a placebo arm and does not establish cognitive enhancement from reducing abdominal fat.
Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.